10 Biotech Stocks You Should Watch In January

Axsome Therapeutics
Axsome Therapeutics

Axsome Therapeutics Inc. (AXSM) is developing novel therapies for the management of central nervous system (CNS) disorders.

The Company has two clinical compounds - AXS-05 and AXS-02.

AXS-05 is currently in a phase III trial for the treatment of treatment-resistant depression, dubbed STRIDE-1, and a phase II/III trial for the treatment of agitation in patients with Alzheimer's disease.

AXS-02 is currently in a phase III trial in complex regional pain syndrome, dubbed CREATE, and a phase III trial in knee osteoarthritis associated with bone marrow lesions, known as COAST-1.

The *interim analysis for CREATE-1 and COAST-1 trials will be conducted by an independent data monitoring committee, and results of the analyses are expected to be available by early January 2018.

*An interim analysis helps to evaluate the trial's success probability while controlling the overall error rates. (Source: Science Direct).

Top-line data from the phase III STRIDE-1 trial of AXS-05 are expected in the first half of 2018.

AXSM traded in a range of $3.53 to $7.10 in the last 1 year. The stock is currently up 1.33% at $5.67.